Direct Acting Oral Anticoagulant Treatment (DOACT) Project
About the Project
From the time a patient with a life-threatening hemorrhage first interfaces with the healthcare system, there are a myriad of potential obstacles to them expeditiously receiving antidotes like andexanet alfa. Little is known about the logistical and socioeconomic factors related to the outcomes associated with andexanet alfa administration specifically compared to prothrombin complex concentrate (PCC).
The Direct-acting Oral Anticoagulant Treatment (DOACT) project will utilize ToxIC’s multi-center network of sites to collect detailed clinical information on patients presenting with an acute life-threatening hemorrhage (i.e., intracranial hemorrhage, gastrointestinal hemorrhage, traumatic hemorrhage, etc) and treatment of andexanet alfa and/or PCC (4-factor PCC).
Site investigators will retrospectively enter cases into a specific DOACT registry created by ToxIC that collects data on patients with life-threatening hemorrhage secondary to a direct-acting oral anticoagulants, specifically a factor Xa inhibitor such as rivaroxaban or apixaban, that receive either andexanet alfa and/or PCC (4-factor PCC) at multiple healthcare sites around the country.Â
Funding
Funding for this initiative was made possible by AstraZeneca Pharmaceuticals.
Principal Investigator:
Alexandra Amaducci, DO
Lehigh Valley Health Network
Bethlehem, PA
Principal Investigator:
Christopher Holstege, MD
University of Virginia
Charlottesville, VA
Principal Investigator:
David Liss, MD
Washington University School of Medicine in St. Louis
St. Louis, MO
Principal Investigator:
Charlotte Goldfine, MD, FACMT
Harvard University
Boston, MA
